Literature DB >> 18710948

TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1.

Shunbin Ning1, Alex D Campos, Bryant G Darnay, Gretchen L Bentz, Joseph S Pagano.   

Abstract

We have recently shown that interferon regulatory factor 7 (IRF7) is activated by Epstein-Barr virus latent membrane protein 1 (LMP1), a member of the tumor necrosis factor receptor (TNFR) superfamily, through receptor-interacting protein-dependent K63-linked ubiquitination (L. E. Huye, S. Ning, M. Kelliher, and J. S. Pagano, Mol. Cell. Biol. 27:2910-2918, 2007). In this study, with the use of small interfering RNA and TNFR-associated factor 6 (TRAF6) knockout cells, we first show that TRAF6 and its E3 ligase activity are required for LMP1-stimulated IRF7 ubiquitination. In Raji cells which are latently infected and express high levels of LMP1 and IRF7 endogenously, expression of a TRAF6 small hairpin RNA construct reduces endogenous ubiquitination and endogenous activity of IRF7. In TRAF6(-/-) mouse embryonic fibroblasts, reconstitution with TRAF6 expression, but not with TRAF6(C70A), which lacks the E3 ligase activity, recovers LMP1's ability to stimulate K63-linked ubiquitination of IRF7. Further, we identify IRF7 as a substrate for TRAF6 E3 ligase and show that IRF7 is ubiquitinated by TRAF6 at multiple sites both in vitro and in vivo. Most important, we determine that the last three C-terminal lysine sites (positions 444, 446, and 452) of human IRF7 variant A are essential for activation of IRF7; these are the first such sites identified. A ubiquitination-deficient mutant of IRF7 with these sites mutated to arginines completely loses transactivational ability in response not only to LMP1 but also to the IRF7 kinase IkappaB kinase epsilon. In addition, we find that K63-linked ubiquitination of IRF7 occurs independently of its C-terminal functional phosphorylation sites. These data support our hypothesis that regulatory ubiquitination of IRF7 is a prerequisite for its phosphorylation. This is the first evidence to imply that ubiquitination is required for phosphorylation and activation of a transcription factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710948      PMCID: PMC2577435          DOI: 10.1128/MCB.00785-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  68 in total

Review 1.  LMP1 structure and signal transduction.

Authors:  A G Eliopoulos; L S Young
Journal:  Semin Cancer Biol       Date:  2001-12       Impact factor: 15.707

2.  Triggering the interferon antiviral response through an IKK-related pathway.

Authors:  Sonia Sharma; Benjamin R tenOever; Nathalie Grandvaux; Guo-Ping Zhou; Rongtuan Lin; John Hiscott
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

Review 3.  TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology.

Authors:  Hao Wu; Joseph R Arron
Journal:  Bioessays       Date:  2003-11       Impact factor: 4.345

Review 4.  Epstein-Barr virus latent membrane protein 1: structure and functions.

Authors:  Hsin-Pai Li; Yu-Sun Chang
Journal:  J Biomed Sci       Date:  2003 Sep-Oct       Impact factor: 8.410

Review 5.  The IRF family transcription factors in immunity and oncogenesis.

Authors:  Tomohiko Tamura; Hideyuki Yanai; David Savitsky; Tadatsugu Taniguchi
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

6.  TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1.

Authors:  U Schultheiss; S Püschner; E Kremmer; T W Mak; H Engelmann; W Hammerschmidt; A Kieser
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

7.  Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2).

Authors:  Chong-Shan Shi; John H Kehrl
Journal:  J Biol Chem       Date:  2003-02-18       Impact factor: 5.157

Review 8.  Tumor necrosis factor receptor-associated factors (TRAFs).

Authors:  J R Bradley; J S Pober
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

9.  Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress.

Authors:  Tony T Huang; Shelly M Wuerzberger-Davis; Zhao-Hui Wu; Shigeki Miyamoto
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

10.  Elucidation of the c-Jun N-terminal kinase pathway mediated by Estein-Barr virus-encoded latent membrane protein 1.

Authors:  Jun Wan; Luguo Sun; Jennifer Woo Mendoza; Yiu Loon Chui; Dolly P Huang; Zhijian J Chen; Nobutaka Suzuki; Shinobu Suzuki; Wen-Chen Yeh; Shizuo Akira; Kunihiro Matsumoto; Zheng-Gang Liu; Zhenguo Wu
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

View more
  62 in total

1.  Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7.

Authors:  Qiming Liang; Hongying Deng; Xiaojuan Li; Xianfang Wu; Qiyi Tang; Tsung-Hsien Chang; Hongzhuang Peng; Frank J Rauscher; Keiko Ozato; Fanxiu Zhu
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

2.  Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production.

Authors:  Jennifer A Young; Decha Sermwittayawong; Hee-Jung Kim; Suruchi Nandu; Namsil An; Hediye Erdjument-Bromage; Paul Tempst; Laurent Coscoy; Astar Winoto
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

Review 3.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

4.  Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.

Authors:  Gretchen L Bentz; Christopher B Whitehurst; Joseph S Pagano
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

5.  Understanding Epstein-Barr Virus Life Cycle with Proteomics: A Temporal Analysis of Ubiquitination During Virus Reactivation.

Authors:  Dong-Wen Lv; Jun Zhong; Kun Zhang; Akhilesh Pandey; Renfeng Li
Journal:  OMICS       Date:  2017-01

6.  LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required.

Authors:  L Wang; J Ren; G Li; J P Moorman; Z Q Yao; S Ning
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

7.  Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon.

Authors:  Qinjie Zhou; Alfonso Lavorgna; Melissa Bowman; John Hiscott; Edward W Harhaj
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

8.  Novel roles of cytoplasmic ICP0: proteasome-independent functions of the RING finger are required to block interferon-stimulated gene production but not to promote viral replication.

Authors:  Kathryne E Taylor; Marianne V Chew; Ali A Ashkar; Karen L Mossman
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors.

Authors:  Rowan Higgs; Elisa Lazzari; Claire Wynne; Joan Ní Gabhann; Alexander Espinosa; Marie Wahren-Herlenius; Caroline A Jefferies
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

10.  TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA.

Authors:  Hiroyasu Konno; Takuya Yamamoto; Kohsuke Yamazaki; Jin Gohda; Taishin Akiyama; Kentaro Semba; Hideo Goto; Atsushi Kato; Toshiaki Yujiri; Takahiko Imai; Yasushi Kawaguchi; Bing Su; Osamu Takeuchi; Shizuo Akira; Yasuko Tsunetsugu-Yokota; Jun-ichiro Inoue
Journal:  PLoS One       Date:  2009-05-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.